DJIA 18,162.99 121.45 0.67%
NASDAQ 5,106.59 73.84 1.47%
S&P 500 2,123.48 19.28 0.92%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

60.57 0.76 (1.26%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $60.57 1.26%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $60.17
Previous Close $59.82
Daily Range $59.69 - $60.80
52-Week Range $38.49 - $75.17
Market Cap $9.0B
P/E Ratio -239.26
Dividend (Yield) $0.00 (0.0%)
Volume 682,521
Average Daily Volume 1,049,730
Current FY EPS -$0.98

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics

Alkermes Plc's ALKS 3831 could help patients that take atypical antidepressants avoid gaining weight.

The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis a

The Zacks Analyst Blog Highlights: Johnson & Johnson, AstraZeneca, ACADIA Pharmaceuticals, Actavis and Alkermes - Press Releases

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Ye

Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

3 Stocks Poised to Grow in the Schizophrenia Market - Analyst Blog

Benzinga's Top Initiations

Top Analyst Upgrades and Downgrades: Alibaba, Mobileye, NetApp, Nike, Salesforce.com, Stratasys and

Top Analyst Upgrades and Downgrades: Alibaba, Mobileye, NetApp, Nike, Salesforce.com, Stratasys and More

4 SMID-Cap Biotechs Barclays Just Confessed It Loves

First Week of ALKS July 17th Options Trading

Top Analyst Upgrades and Downgrades: Alkermes, Cisco, Gap, Rackspace, SouFun, Verizon and More

Alkermes' Q1 Loss Narrower than Expected, Maintains View - Analyst Blog

Alkermes (ALKS) Earnings Report: Q1 2015 Conference Call Transcript

See More ALKS News...

ALKS's Top Competitors

ALKS $60.57 (1.26%)
Current stock: ALKS
AMGN $160.44 (0.90%)
Current stock: AMGN
GILD $112.46 (2.45%)
Current stock: GILD
BIIB $402.92 (2.56%)
Current stock: BIIB